CN102036976B - 多巴胺神经传递的调节剂 - Google Patents

多巴胺神经传递的调节剂 Download PDF

Info

Publication number
CN102036976B
CN102036976B CN200980115417XA CN200980115417A CN102036976B CN 102036976 B CN102036976 B CN 102036976B CN 200980115417X A CN200980115417X A CN 200980115417XA CN 200980115417 A CN200980115417 A CN 200980115417A CN 102036976 B CN102036976 B CN 102036976B
Authority
CN
China
Prior art keywords
methyl
dihydro
methylsulfonyl
amine
nitrae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980115417XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102036976A (zh
Inventor
C·索尼森
P·斯文森
J·卡尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
NSAB Filial af Neurosearch Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NSAB Filial af Neurosearch Sweden AB filed Critical NSAB Filial af Neurosearch Sweden AB
Publication of CN102036976A publication Critical patent/CN102036976A/zh
Application granted granted Critical
Publication of CN102036976B publication Critical patent/CN102036976B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200980115417XA 2008-04-29 2009-04-28 多巴胺神经传递的调节剂 Expired - Fee Related CN102036976B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200800598 2008-04-29
DKPA200800598 2008-04-29
US4905908P 2008-04-30 2008-04-30
US61/049,059 2008-04-30
PCT/EP2009/055137 WO2009133107A1 (en) 2008-04-29 2009-04-28 Modulators of dopamine neurotransmission

Publications (2)

Publication Number Publication Date
CN102036976A CN102036976A (zh) 2011-04-27
CN102036976B true CN102036976B (zh) 2013-05-01

Family

ID=40940061

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980115417XA Expired - Fee Related CN102036976B (zh) 2008-04-29 2009-04-28 多巴胺神经传递的调节剂

Country Status (15)

Country Link
US (1) US8524766B2 (enExample)
EP (1) EP2271634B1 (enExample)
JP (1) JP5514804B2 (enExample)
KR (1) KR20100135325A (enExample)
CN (1) CN102036976B (enExample)
AU (1) AU2009242092A1 (enExample)
BR (1) BRPI0911772A2 (enExample)
CA (1) CA2722978A1 (enExample)
DK (1) DK2271634T3 (enExample)
IL (1) IL208289A0 (enExample)
MX (1) MX2010011724A (enExample)
NZ (1) NZ588209A (enExample)
RU (1) RU2010141964A (enExample)
WO (1) WO2009133107A1 (enExample)
ZA (1) ZA201006932B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2271635A1 (en) * 2008-04-29 2011-01-12 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
MX2010011498A (es) 2008-04-29 2010-11-12 Nsab Af Neurosearch Sweden Ab Moduladores de neurotransmision de dopamina.
CN102180856B (zh) * 2011-03-01 2016-01-20 浙江华海药业股份有限公司 一种制备6-氟-3,4-二氢-2h-1-苯并吡喃-2-甲酸乙酯的方法
JP5876140B2 (ja) 2011-04-19 2016-03-02 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質のドーパミン作動性及びｎｍｄａ受容体介在のグルタミン酸作動性神経伝達の新規なモジュレータ
KR20160027218A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
JP6481689B2 (ja) 2014-06-26 2019-03-13 住友化学株式会社 フェノール化合物の製造方法
US9125866B1 (en) 2015-01-28 2015-09-08 King Saud University Antidepressant compounds
CH712810B1 (de) * 2015-07-21 2020-07-15 Sumitomo Chemical Co Verfahren zur Herstellung einer 4-(Trifluormethylsulfonyl)phenol-Verbindung.
WO2020239568A1 (en) 2019-05-24 2020-12-03 Integrative Research Laboratories Sweden Ab Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
WO2024182774A1 (en) * 2023-03-01 2024-09-06 Alexander Shulgin Research Institute, Inc. Deuterated and fluorinated empathogens

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3058980A (en) * 1962-10-16 Substitution products of benzo-
US2906757A (en) * 1959-09-29 Their preparation
DE1110175B (de) * 1957-01-08 1961-07-06 Rhone Poulenc Sa Verfahren zur Herstellung von Benzodioxanderivaten
JPS55124781A (en) * 1979-03-20 1980-09-26 Shionogi & Co Ltd 1,4-benzdioxanesulfonamide derivative
US5236055A (en) * 1991-03-13 1993-08-17 Canadian Aging & Rehabilitation Product Development Corporation Wheel with coaxial drive system mounted in the wheelhub field of the invention
US5189171A (en) * 1991-06-21 1993-02-23 American Home Products Corporation Antipsychotic benzodioxan derivatives
US5166367A (en) * 1991-06-21 1992-11-24 American Home Products Corporation Antipsychotic benzodioxan derivatives
US5126366A (en) * 1991-06-21 1992-06-30 American Home Products Corporation Aminophenoxyalkyl derivatives of benzodioxan
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5235055A (en) 1992-09-02 1993-08-10 American Home Products Corporation Antipsychotic quinoline derivatives of benzodioxanmethylamine
US5245051A (en) * 1992-09-03 1993-09-14 American Home Products Corporation Antipsychotic chroman derivatives of benzodioxanmethylamine
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
US5663194A (en) * 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
US5684039A (en) * 1995-07-25 1997-11-04 American Home Products Corporation Chroman-2-ylmethylamino derivatives
AR004229A1 (es) * 1995-11-06 1998-11-04 Wyeth Corp Derivados indolalquilo de benzodioxanmetilamina y su uso para preparar medicamentos
FR2791675B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
GB0007376D0 (en) 2000-03-28 2000-05-17 Knoll Ag Therapeutic agents
JP2005505586A (ja) * 2001-10-04 2005-02-24 ワイス ５−ヒドロキシトリプタミン−６リガンドとしてのクロマン誘導体
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
US20070208166A1 (en) * 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use
NZ550441A (en) * 2004-05-05 2009-07-31 Hoffmann La Roche Arylsulfonyl benzodioxanes useful for modulating the 5-HT6 receptor, the 5-HT2A receptor or both
KR101245075B1 (ko) * 2004-06-08 2013-03-18 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 도파민 신경전달의 모듈레이터로서 신 2기치환된페닐피페리딘/피페라진
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
BRPI0610046A2 (pt) * 2005-04-22 2010-05-25 Wyeth Corp derivados de benzodioxano e benzodioxolano e usos destes
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
AR060493A1 (es) * 2006-04-18 2008-06-18 Wyeth Corp Derivados de benzodioxano y benzodioxolano. procesos de obtencion.
EP2026790A2 (en) * 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
TWI457122B (zh) * 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
EP2271635A1 (en) 2008-04-29 2011-01-12 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
MX2010011498A (es) 2008-04-29 2010-11-12 Nsab Af Neurosearch Sweden Ab Moduladores de neurotransmision de dopamina.

Also Published As

Publication number Publication date
US8524766B2 (en) 2013-09-03
US20110105461A1 (en) 2011-05-05
MX2010011724A (es) 2010-11-30
AU2009242092A1 (en) 2009-11-05
ZA201006932B (en) 2011-12-28
CN102036976A (zh) 2011-04-27
EP2271634A1 (en) 2011-01-12
DK2271634T3 (da) 2014-05-05
NZ588209A (en) 2012-08-31
JP2011518858A (ja) 2011-06-30
BRPI0911772A2 (pt) 2017-06-27
EP2271634B1 (en) 2014-02-12
JP5514804B2 (ja) 2014-06-04
WO2009133107A1 (en) 2009-11-05
IL208289A0 (en) 2010-12-30
KR20100135325A (ko) 2010-12-24
RU2010141964A (ru) 2012-06-10
CA2722978A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
CN102036976B (zh) 多巴胺神经传递的调节剂
CA2832874C (en) Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission
CN102224136B (zh) 用作皮质儿茶酚胺能神经传递调节剂的3-苯基-3-甲氧基-吡咯烷衍生物
CN102015674B (zh) 多巴胺神经传递调节剂
US20110105462A1 (en) Modulators of dopamine neurotransmission
EP2367786B1 (en) Novel 1 -alkyl- 3 -hydroxy- 3 -phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
JP5621087B2 (ja) 皮質のカテコールアミン作動性神経伝達のモジュレーターとして有用な新規な３−フェニル−アゼチジン誘導体
HK1162172A (en) Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20161026

Address after: Gothenburg

Patentee after: NEUROSEARCH A/S

Address before: Denmark and Rupp

Patentee before: NSAB Filial af NeuroSearch Sweden AB Sverige

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130501

CF01 Termination of patent right due to non-payment of annual fee